At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,807 enrolled
Drug / intervention
Tofacitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of Tumor Necrosis Factor (TNF) Inhibitors and Tofacitinib, Overall, by Line of Therapy and by Combination Therapy
In Brief
An observational study evaluating Tofacitinib for Arthritis Rheumatoid. Completed, enrolled 7,807 participants across 1 site.
Detailed Summary
This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis Rheumatoid
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedJan 2021
Primary CompletionNov 2021
TodayJul 2026
First PostedJan 25, 2021
Enrollment StartJan 22, 2021
Primary CompletionNov 29, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.4 years ago
Interventions
Tofacitinibdrug
Patients who received Tofacitinib for RA